Search Results
Nov 03, 2025, 11:03 ET BrainXell Therapeutics Unveils Promising Preclinical Data Demonstrating Efficacy of BXT-110, an Autologous iPSC-Derived Neuronal Therapy, in Parkinson's Disease
Therapeutics today announced the disclosure of its first scientific data, which will be presented at two conferences this month: the Cell Symposia | Gene and Cell-Based Therapies: Progress in Clinical Translation and the Society for Neuroscience (SfN) Annual Meeting. These presentations mark a significant
More news about: BrainXell, Inc.
Nov 03, 2025, 10:35 ET Answer ALS Completes Release of Full Dataset and Integrates ALS TDI ARC Study Data into Neuromine
collected and analyzed a rich array of biological data from each participant, including genomics: whole-genome DNA sequencing data; transcriptomics: gene expression profiles (RNA sequencing); proteomics: protein expression and biomarker data; epigenomics: epigenetic markers (e.g., DNA methylation); and
More news about: Answer ALS
Nov 03, 2025, 09:05 ET Enliven Therapeutics Announces Clinical Data in CML Patients with Atypical Fusion Transcripts at ASH 2025 Annual Meeting
ELVN-001ELVN-001 is a potent, highly selective, potentially best-in-class small molecule kinase inhibitor designed to specifically target the BCR::ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. As a highly selective active site inhibitor, ELVN-001 has a mechanism of action
More news about: Enliven Therapeutics, Inc.
Nov 03, 2025, 09:00 ET Sumitomo Pharma America to Present New Investigational Data at the 2025 American Society of Hematology Annual Meeting
a scaffold protein that controls gene expression and cell signaling. Trends Biochem Sci. 2013; 38(8):394-402. doi:10.1016/j.tibs.2013.05.005. Kuhn MWM, Song E, Feng Z, et al. Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia.
More news about: Sumitomo Pharma America
Nov 03, 2025, 08:30 ET Xtalks Announces its Life Science Webinar Calendar for November 2025
Upcoming free, educational webinars from Xtalks will feature topics on biomarkers, cell and gene therapy, clinical trials, commercialization & HEOR, drug discovery & development, drug safety, healthcare, patient recruitment & retention, pharma
More news about: Xtalks
Nov 03, 2025, 08:30 ET Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference
next generation conditioning candidate, is being developed with the goal of improving patient access and outcomes for potentially curative cell and gene therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which Actinium is seeking a potential
More news about: Actinium Pharmaceuticals, Inc.
Nov 03, 2025, 08:00 ET Matica Bio, a CDMO Leader in Oncolytic Virus Manufacturing, Partners with Calidi Biotherapeutics to Advance Calidi's Project Toward IND
is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent gene therapies to metastatic locations. The lead candidate from the Redtail platform, currently in IND-enabling studies, targets non-small
More news about: Matica Biotechnology, Inc.
Nov 03, 2025, 08:00 ET Ginkgo Bioworks Awarded Project Agreement through BARDA's BioMaP-Consortium
industry, government, and academic entities, ABL provides manufacturing capabilities for the development and production of virus-based oncolytic therapies, gene therapies and viral vaccines. GMP facilities are in Rockville, MD with services including bulk drug substance, live virus fill/finish, process, and
More news about: Ginkgo Bioworks
Nov 03, 2025, 07:00 ET ScaleReady Announces a G-Rex® Grant has been awarded to Sonoma Biotherapeutics
G-Rex® Grant. SonomaBio's G-Rex® Grant will enable expeditious development of a G-Rex® based manufacturing process to produce gene-modified regulatory T cell (Treg) therapies for clinical investigation of SonomaBio products in development for various autoimmune related disorders.
More news about: Bio-Techne Corporation
Nov 03, 2025, 07:00 ET Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress
and delayed menopause.5 TP53 is a well-recognized prognostic marker for EC; >50% of advanced or recurrent EC tumors are TP53wt (gene for tumor protein P53; wild-type), and ~40%-55% are both TP53wt and mismatch repair-proficient (pMMR).6-8 While immune checkpoint
More news about: Karyopharm Therapeutics Inc.
Oct 31, 2025, 09:00 ET Mickey Thompson Named Official Tire and Wheel Sponsor of Jeep Jamboree USA and Jeep Adventure Academy
Wheels offers performance, racing and off-road tires and wheels. Headquartered in Stow, Ohio, USA, the company was founded in 1963 by Mickey Thompson and Gene McMannis. Today, Mickey Thompson Tires & Wheels markets their products globally, empowering automotive enthusiasts, competitive racers, and weekend
More news about: The Goodyear Tire & Rubber Company
Oct 31, 2025, 07:09 ET Kexing Biopharm Showcases Global Strategy and Partnership Opportunities at CPHI Frankfurt 2025
engages in the R&D, manufacture and sales of innovative medicines of distinct modalities including recombinant proteins, antibodies, and cellular/gene therapies. Through building cutting-edge technology platforms to advance the development of novel targeted therapies and drug
More news about: Kexing Biopharm
Oct 31, 2025, 06:46 ET GITEX GLOBAL 2025: Record international participation and outcome-driven dialogues close landmark 45th edition
founders unveiled next-gen innovations: smart contact lenses that estimate glucose from biomarkers, brain-computer implants decoding neural signals, and AI gene-editing tech reprogramming DNA for disease resistance. In infrastructure, chipmakers and cloud giants unveiled next-generation semiconductors and hyperscale
More news about: GITEX
Oct 31, 2025, 06:44 ET GITEX GLOBAL 2025: Record international participation and outcome-driven dialogues close landmark 45th edition
founders unveiled next-gen innovations: smart contact lenses that estimate glucose from biomarkers, brain-computer implants decoding neural signals, and AI gene-editing tech reprogramming DNA for disease resistance. In infrastructure, chipmakers and cloud giants unveiled next-generation semiconductors and hyperscale
More news about: GITEX
Oct 31, 2025, 06:22 ET Weekly Recap: 13 Health Press Releases You Need to See
Biotechnologies This acquisition aligns Lilly's genetic medicine capabilities with the opportunity to expand gene therapy's potential to alleviate the burden of age-related diseases.
More news about: PR Newswire
Oct 31, 2025, 04:00 ET Vesper Bio announces positive Phase Ib/IIa topline results for lead candidate VES001 for frontotemporal degeneration
Ib/IIa SORT-IN-2 clinical study evaluating VES001 in asymptomatic carriers with frontotemporal degeneration (FTD) caused by mutations in the progranulin gene (GRN). Mean progranulin levels increased by more than 95% compared to baseline at the highest dose tested. As individuals with
More news about: Vesper Bio
Oct 30, 2025, 19:08 ET EXPO 2025大阪・関西万博（Osaka Expo 2025）の中国パビリオンが金賞を受賞！Uniluminが包括的なマルチメディア・ソリューションを提供
Vitality）」という詩的な章が、LEDディスプレイ、プロジェクション、レーダー・システムによるインタラクティブ体験の融合によって表現されました。これにより、来場者は没入型空間で時間と自然の間を旅するような感覚を味わうことができました。 Uniluminのチームはさらに革新的に「文化デジタル遺伝子バンク（Cultural Digital Gene Bank）」を創出し、水墨画、絹、山水画といった東洋的要素をデジタル言語へと変換しました。これらの要素は他の展示アイテムにも柔軟に応用されました。「適応型環境光調整システム（Adaptive Ambient Light Adjustment System）」と組み合わせることで、LEDビジュアル・ディスプレイのインタラクティブ端末は建築空間とミリメートル単位の統合を実現しました。
More news about: Unilumin Group., Ltd.
Oct 30, 2025, 17:31 ET Atypical Teratoid/Rhabdoid Tumor Treatment Market Shows Promising CAGR During the Forecast Period (2025-2034) with Growing Clinical Trials and R&D Initiatives | DelveInsight
highly malignant tumor of the central nervous system (CNS), most commonly affecting young children. It is characterized by loss of the SMARCB1 (INI1) gene, or, less frequently, SMARCA4, resulting in disruption of the SWI/SNF chromatin-remodeling complex and widespread epigenetic dysregulation. Clinically,
More news about: DelveInsight Business Research, LLP
Oct 30, 2025, 16:05 ET Illumina Reports Financial Results for Third Quarter of Fiscal Year 2025
to the Alliance for Genomic Discovery (AGD), broadening the consortium's diverse clinical genomic dataset and utilizing it to inform development of 'gene silencing' medicines Introduced Illumina® Protein Prep, driving deeper proteomic insights to enhance drug discovery and development,
More news about: Illumina, Inc.
Oct 30, 2025, 10:35 ET Cardiovascular, Renal & Metabolic (CRM) Diseases Market to Reach USD 451.87 Billion by 2033, Driven by Rising Burden of Chronic Conditions | DataM Intelligence
consulting, and competitive intelligence solutions. The firm's oncology market coverage spans hematologic malignancies, solid tumors, and cell & gene therapies, providing deep-dive data on clinical pipelines, regulatory landscapes, pricing, and market access strategies.
More news about: DataM Intelligence 4 Market Research LLP
Oct 30, 2025, 10:30 ET Cystic Fibrosis (CF) Therapeutics Market to Reach $17.1 billion by 2027 in the short term and $32.3 billion by 2034 Globally, at 9.6% CAGR: Allied Market Research
the respiratory and digestive systems. CF is caused by mutations in the CFTR gene, leading to thick mucus buildup in various organs. Over recent years, the market has witnessed significant growth due to advancements in gene-targeted therapies, including CFTR modulators such as ivacaftor, lumacaftor,
More news about: Allied Market Research
Oct 30, 2025, 10:01 ET Livestock Genomics Testing Market to Reach $3,691.4 million, Globally, by 2034 at 9.3% CAGR: Allied Market Research
Market by Test Type (Genotyping Services, Whole Genome Sequencing (WGS), Trait Testing, Genomic Selection (gEBV), Embryo Testing, Disease Gene Screening, and Others) and Application (Selective Breeding, Productivity Enhancement, Food Safety, Disease Resistance, and Others): Global Opportunity
More news about: Allied Market Research
Oct 30, 2025, 10:00 ET Pillar Biosciences Announce Automated NGS Library Preparation Method on Hamilton Microlab STAR to Accelerate Myeloproliferative Neoplasm Research
oncoReveal® Essential MPN, a rapid 3-gene NGS panel designed to quickly streamline the evaluation of myeloproliferative neoplasms (MPN) through the interrogation of JAK2, CALR and MPL, is the
More news about: Pillar Biosciences, Inc.
Oct 30, 2025, 08:52 ET Global Location Strategies Report: $350 Billion U.S. Pharmaceutical Manufacturing Investment Boom Challenged by Labor Shortages, Tariffs and Policy Shifts
U.S. remains the world's largest biologics market (48% of global revenues). Therapeutic biologics, such as monoclonal antibodies, recombinant proteins, gene and cell therapies, and therapeutic vaccines, represent the fastest-growing segment of global medicine, transforming treatment for cancer, autoimmune
More news about: Global Location Strategies
Oct 30, 2025, 08:30 ET Cryoport Continues to Set New Benchmarks for the Global Regenerative Medicine Supply Chain
ISO 21973 Certification, Ensuring Highest Transport Safety, Traceability, and Integrity Standards for Cell and Gene Therapies NASHVILLE, Tenn., Oct.
More news about: Cryoport, Inc.